P2RY12 and ischemia: While lowering bleeding risks without increasing ischemia risk, previous meta-analyses show that in patients undergoing complex PCI, P2Y12 inhibitor monotherapy offers greater safety regarding major bleeding events and does not raise the risk of ischemic incidents compared to standard DAPT.